By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter
In 2017, UK-based gene and cell therapy company Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce Big Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel). The deal could be worth upwards of $100 million over its three-year span.